Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] - Ionis Pharmaceuticals Inc. [Member] $ in Millions |
Aug. 01, 2016
USD ($)
|
|---|---|
| Subsequent Event [Line Items] | |
| Litigation settlement, upfront payment | $ 1.4 |
| Royalty payment percentage | 5.00% |
| Sale, license or other transaction payment percentage | 50.00% |
| Maximum [Member] | |
| Subsequent Event [Line Items] | |
| Litigation settlement, success based payment | $ 5.0 |
| Sale, license or other transaction payment percentage | 50.00% |
| X | ||||||||||
- Definition Litigation settlement, additional royalty payment as percentage of net sales of licensed product. No definition available.
|
| X | ||||||||||
- Definition Litigation settlement, payment as percentage of money received from sale, license or other transaction of licensed product. No definition available.
|
| X | ||||||||||
- Definition Amount of damages paid to the plaintiff in the legal matter. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The difference between the maximum amount of estimated loss and the amount recorded as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|